Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer

Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect.

Bhavna brings nearly two decades of experience across biotechnology, investment banking, and strategic consultancy to Nucleome. In her role, she will lead corporate and business development activities including developing and executing the business development strategy, identifying and pursuing strategic business opportunities aligned with Nucleome’s vision, and supporting company growth and financing.

Prior to Nucleome, Bhavna was Chief Business Officer and Board Director at C4X Discovery where she played a critical role in a series of successful licensing deals and partnerships, as well as driving business growth and capital raising as part of the Executive Management team. Previous to this, Bhavna held corporate and commercial roles at Lehman Brothers, Nomura International, PwC and Cancer Research UK. Bhavna holds a First Class degree in Biochemistry from Oxford University.

Dr Mark Bodmer, CEO of Nucleome, said: “I am delighted to welcome Bhavna to Nucleome, with her great breadth of experience and ability. Our proprietary lab-plus-machine learning technology is a transformative use of human genetics to discover the molecular basis of disease. This is yielding an emerging pipeline of first-in-class, highly differentiated, inflammatory disease programs. Bhavna will play an essential role in the next phase of company growth with outstanding scientific, clinical and commercial execution of the pipeline and technology”.